Table 3.

Risk of renal relapse after adjustment for duration of hematuria and proteinuria in ANCA-associated vasculitis

Variable	sHR (95% CI)	P Value
Cumulative duration of hematuria (per mo)	1.08 (1.03 to 1.12)	<0.01
Cumulative duration of proteinuria (per mo)	1.04 (0.99 to 1.08)	0.10
ANCA (anti-PR3 versus anti-MPO)	0.77 (0.30 to 1.92)	0.57
Baseline pulmonary involvement	2.84 (0.34 to 23.98)	0.34
Baseline creatinine per 1 mg/dl	0.94 (0.48 to 1.83)	0.85
Study (the RAVE Trial versus the WGET)	0.30 (0.06 to 1.64)	0.17

Cumulative durations of hematuria and proteinuria were analyzed as time-varying covariates. Hematuria by proteinuria interaction was not significant (P for interaction =0.11). sHR, subdistribution hazard ratio; 95% CI, 95% confidence interval; PR3, proteinase 3; MPO, myeloperoxidase; RAVE, Rituximab in ANCA-Associated Vasculitis; WGET, Wegener’s Granulomatosis Etanercept Trial.